Nav: Home

Selexipag in pulmonary arterial hypertension: Added benefit not proven

October 06, 2016

Selexipag (trade name: Uptravi) is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms. The drug can be used either as combination therapy with other blood-pressure lowering drugs or as monotherapy in patients who are not candidates for these therapies. Selexipag has been on the market in Germany since May 2016. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether this drug has advantages or disadvantages in comparison with the appropriate comparator therapy.

The limitation of the comparator therapy to a specific drug and the subsequent division of the population in the dossier were inadequate. The only study cited by the drug manufacturer for one of its subpopulations compared selexipag with placebo. However, no added benefit can be inferred from such a comparison.

Hence the manufacturer presented no suitable data for the assessment of the added benefit of selexipag, and IQWiG concluded: An added benefit of selexipag in comparison with the appropriate comparator therapy is not proven.

Selective widening of vessels and inhibition of tissue growth

In PAH, the pulmonary artery is narrowed, and the heart has to work harder to pump oxygen-poor blood through the pulmonary artery into the lungs. The permanently increased workload of the right heart chamber decreases the body's oxygen supply. The high blood pressure (hypertension) is often caused by another heart or lung disease, e.g. by chronic obstructive pulmonary disease (COPD) or a congenital heart defect.

Selexipag aims to widen the pulmonary artery and slow down the overload of the heart. The drug is approved for long-term treatment of PAH patients who have no symptoms at rest but who have slight (WHO functional class II) or marked (WHO functional class III) limitation of physical activity. These restrictions cause symptoms such as dyspnoea, tiredness, chest pain, or dizziness. Selexipag is an option as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase-5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.

Manufacturer deviated from appropriate comparator therapy

The Federal Joint Committee (G-BA) specified individually optimized drug treatment specified by the physician under consideration of the respective approval status as appropriate comparator therapy.

The manufacturer deviated from this specification and considered only iloprost as an option of an individual drug treatment. It did also not use individual optimization.

In addition, the manufacturer distinguished between two subpopulations: Its "subpopulation a" comprised patients for whom also iloprost is not an option, and for whom therefore only watchful waiting until worsening of the PAH is available. Its "subpopulation b" comprised patients for whom iloprost is an option.

The limitation of the comparator therapy and the subsequent division of the population was inadequate. The Institute therefore used the appropriate comparator therapy specified by the G-BA, without division of the patient population, for the dossier assessment.

Study with placebo comparison unsuitable

The manufacturer cited a randomized controlled trial (GRIPHON) for its "subpopulation a", in which iloprost was not an option: At the start of the study, treatment in the intervention arm was expanded by administration of selexipag. There was no treatment expansion in the control arm; the patients received only placebo. In both treatment arms, it was not allowed to adjust the ongoing medication for treatment of the PAH. Iloprost was approved for about half of the patients included in the study (WHO functional class III), which contradicts the manufacturer's definition of its "subpopulation a".

The study only allowed a comparison of selexipag with placebo and was therefore unsuitable to draw conclusions on the added benefit of selexipag: The study design allowed individual adjustment of the PAH-specific treatment in case of worsening of the PAH. If the PAH worsened, however, the blinded and randomized treatment phase for the patient ended according to the study protocol.

G-BA decides on the extent of added benefit

The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as easily understandable information on If you would like to be informed when these documents are available, please send an e-mail to

Institute for Quality and Efficiency in Health Care

Related Placebo Articles:

Botulinum toxin reduces chronic migraine attacks, compared to placebo
A growing body of evidence supports the effectiveness of botulinum toxin injections in reducing the frequency of chronic migraine headaches, concludes an updated review and analysis in the January issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).
Opioids vs. placebo, nonopioid alternatives for chronic noncancer pain
An estimated 50 million adults in the United States were living with chronic noncancer pain in 2016 and many of them were prescribed opioid medications, even though a clinical benefit is uncertain.
Probiotic no better than placebo for acute gastroenteritis in children
While probiotics are often used to treat acute gastroenteritis (also known as infectious diarrhea) in children, the latest evidence shows no significant differences in outcomes, compared to a placebo.
Most common shoulder operation is no more beneficial than placebo surgery
In a landmark study published this week in the BMJ, Finnish researchers show that one of the most common surgical procedures in the Western world is probably unnecessary.
Omega-3s from fish oil supplements no better than placebo for dry eye
Omega-3 fatty acid supplements taken orally proved no better than placebo at relieving symptoms or signs of dry eye, according to the findings of a well-controlled trial funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Review of Vitamin D Research identifies ethical issues in placebo use
George Washington University's Dr. Leigh Frame reviewed several studies using placebo groups in clinical trials that may pose ethical issues.
Hydroxychloroquine no more effective than placebo for relieving osteoarthritis hand pain
Hydroxychloroquine is no more effective than placebo for relieving moderate to severe hand pain and radiographic osteoarthritis.
Study of heart stents for stable angina highlights potential of placebo effect
Researchers at Imperial College London have explored the placebo effects of a coronary angioplasty procedure with stents for the first time.
Haloperidol as adjunctive therapy superior to placebo for acute gastroparesis symptoms
Haloperidol is an effective first-line agent in combination with standard analgesic and antiemetic agents for the treatment of gastroparesis in the emergency department.
New study on the placebo effect and antidepressants in children and adolescents
Although the clinical efficacy of antidepressants in children and adolescents is proven, it is frequently accompanied by side effects.
More Placebo News and Placebo Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.